7th Jun 2021 12:22
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) | J.P. Morgan Securities LLC |
Company dealt in | Xeris Pharmaceuticals, Inc. |
Class of relevant security to which the dealings being disclosed relate (Note 2) | $0.001 common stock |
Date of dealing | 04 June 2021 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
| Long | Short | ||||
| Number |
| (%) | Number |
| (%) |
(1) Relevant securities | 4,119,967 6.21 | 737,985 1.11 | ||||
(2) Derivatives (other than options) | 593,102 0.89 | 0.00 | ||||
(3) Options and agreements to purchase/sell | 0.00 | 0.00 | ||||
Total | 4,713,069 7.10 | 737,985 1.11 | ||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale |
Number of relevant securities |
Price per unit (USD)
(Note 5) |
Purchase(New Borrow)
Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase Purchase
Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale Sale |
377,800
500 100 7,500 100 4,500 3,700 300 310 2,318 2,380 500 16,239 100 400 23
501 500 244 310 275 300 173 101 200 2,380 500 224 500 500 16,400 65 |
N/A
4.3800 USD 4.2402 USD 4.2250 USD 4.2202 USD 4.2150 USD 4.2050 USD 4.2002 USD 4.1910 USD 4.0869 USD 4.0861 USD 4.0540 USD 4.0500 USD 4.0450 USD 4.0438 USD 4.0100 USD
4.3900 USD 4.3800 USD 4.2384 USD 4.1910 USD 4.1000 USD 4.0967 USD 4.0950 USD 4.0901 USD 4.0900 USD 4.0861 USD 4.0780 USD 4.0777 USD 4.0600 USD 4.0540 USD 4.0500 USD 4.0100 USD |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (USD) (Note 5) |
Equity Swap | Decrease Long
Increase Long
Opening a long position
Opening a short position | 2,380
310
500
500 | 4.0861 USD
4.1910 USD
4.3800 USD
4.0540 USD |
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option | Writing, selling, purchasing, varying etc. | Number of securities to which the option relates (Note 7) | Exercise price | Type, e.g. American, European etc. | Expiry date | Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
(ii) Exercising
Product name, e.g. call option | Number of securities | Exercise price per unit (Note 5) |
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any
other person relating to the voting rights of any relevant securities under any option referred to on this
form or relating to the voting rights or future acquisition or disposal of any relevant securities to which
any derivative referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure | 07 June 2021 |
Contact name | Alwyn Basch |
Telephone number | 0207 742 7407 |
If a connected EFM, name of offeree/offeror with which connected | N/A |
If a connected EFM, state nature of connection (Note 10) | N/A |
Related Shares:
Xeris Biopharma